kabutan

Eisai Co., Ltd.(4523) Summary

4523
TSE Prime
Eisai Co., Ltd.
4,270
JPY
-60
(-1.39%)
Jan 29, 3:30 pm JST
27.91
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
4,280.1
Jan 29, 3:24 pm JST
Summary Chart Historical News Financial Result
PER
29.0
PBR
1.41
Yield
3.75%
Margin Trading Ratio
19.70
Stock Price
Jan 29, 2026
Opening Jan 29, 9:03 am
4,252 JPY 27.76 USD
Previous Close Jan 28
4,330 JPY 28.37 USD
High Jan 29, 1:57 pm
4,297 JPY 28.08 USD
Low Jan 29, 9:07 am
4,211 JPY 27.50 USD
Volume
1,641,900
Trading Value
6.99B JPY 0.05B USD
VWAP
4257.3 JPY 27.83 USD
Minimum Trading Value
427,000 JPY 2,791 USD
Market Cap
1.25T JPY 8.19B USD
Number of Trades
3,840
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
3,637
1-Year High May 15, 2025
11,589
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 44,600 1,864,000 41.79
Jan 16, 2026 38,200 1,835,600 48.05
Jan 9, 2026 64,900 1,629,200 25.10
Dec 26, 2025 60,600 1,705,300 28.14
Dec 19, 2025 52,100 1,908,300 36.63
Company Profile
Eisai Co., Ltd. is a major pharmaceutical company with strengths in neurology and gastrointestinal oncology. The company has expanded into the field of dementia treatments.
Sector
Pharmaceuticals
Eisai's pharmaceutical business accounts for 90% of its sales, encompassing research and development, manufacturing, and sales of both prescription and over-the-counter medicines. The company has a strong global presence with a high overseas sales ratio. Outside Japan, Eisai operates in North America, China, EMEA (Europe, Middle East, Africa, Russia, and Oceania), and Asia-Latin America (South Korea, Taiwan, India, ASEAN, and Latin America). Internationally, Eisai conducts business through its subsidiaries in various regions. In Japan, the company collaborates with group companies such as KAN Research Institute and EA Pharma to advance its operations. In the United States, Eisai markets an Alzheimer's disease treatment that gained attention as the world's first medication to demonstrate a reduction in early clinical symptom progression during clinical trials. Leveraging its global research and development infrastructure and sales network, Eisai aims to provide pharmaceuticals that meet the needs of patients worldwide.